Database Member Home
RAS Member Home
Regulatory restrictions and growing competition have made it increasingly important for biopharmaceutical organizations to develop a tactical approach to Key Opinion Leader (KOL) engagement. Identifying what Key Opinion Leaders value in their relationship and evaluating key KOL activities will help organizations in their KOL management efforts.
This video outlines the top things thought leaders seem to value most in their relationship with organizations and tactics that help build robust Key Opinion Leader relationships. It also provides strategic inputs on the involvement and role of Medical Science Liaisons (MSLs) in Thought Leader Management.
The study benchmarks the organizational structures, management strategies, activities, tools and tactics associated with excellence in KOL management. MA leaders will gain an understanding of approaches to KOL management at leading companies.
A must-have for all pharmaceutical, biotech and medical device manufacturing executives, this Best Practices' R&D Quality Assurance bundle tells you everything you need to know about quality... (ID OPS-95)
Read More »
Best Practices’ Market Research series highlights best practices in market research... (ID SMS-169)
Best Practices’ Pharma Thought Leadership series examines thought leadership in the context of patient advocacy while creating effective relationships and global product launches... (ID SMS-156)
The objective of this benchmarking study is to help biopharma leaders develop competitive launch and pre-launch activity budgets to ensure successful U... (ID PSM-326)
Pharmaceutical and biotech companies are increasingly under pressure to deliver effective new products in shorter time frames while minimizing development costs... (ID PSM-229)
The biopharmaceutical sector has seen dozens of new product launches in the last few years, including some notable new drugs targeting the oncology therapeutic area... (ID PSM-267)
The biopharmaceutical sector has seen dozens of new product launches in the last few years, including some notable new drugs targeting the metabolic therapeutic area... (ID PSM-266)
The biopharmaceutical sector has seen dozens of new product launches in the last few years, including some notable new drugs targeting the cardiovascular therapeutic area... (ID PSM-264)